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The anaphase-promoting complex/cyclosome (APC/
C) is an E3 ubiquitin ligase that targets substrates for
degradation to promote mitotic progression. Here,
we show that the DNA damage response protein
53BP1 contains conserved KEN boxes that are
required for APC/C-dependent degradation in early
mitosis. Mutation of the 53BP1 KEN boxes stabilized
the protein and extended mitotic duration, whereas
53BP1 knockdown resulted in a shorter and delayed
mitosis. Loss of 53BP1 increased APC/C activity,
and we show that 53BP1 is a direct APC/C inhibitor.
Although 53BP1 function is not absolutely required
for normal cell cycle progression, knockdown was
highly toxic in combination with mitotic spindle poi-
sons. Moreover, chemical inhibition of the APC/C
was able to rescue the lethality of 53BP1 loss. Our
findings reveal a reciprocal regulation between
53BP1 and APC/C that is required for response to
mitotic stress and may contribute to the tumor-sup-
pressor functions of 53BP1.
INTRODUCTION
The prevention of aneuploidy is of paramount importance for the
maintenance of genome stability. Transgenic mice that are het-
erozygous for genes that control mitotic progression such as
CENP-E, Mad2, and BubR1 are more susceptible to low levels
of numerical chromosomal instability (CIN) and cancer (Janssen
et al., 2009; Michel et al., 2001; Silk et al., 2013). However,
inducing high levels of CIN by ablating the expression of genes
important for mitosis represses cancer progression by in-
creasing the proportion of cells that die during mitosis.
The anaphase-promoting complex/cyclosome (APC/C) is
required for eukaryotic cell division. It is an E3 ubiquitin ligase
that ubiquitinates regulators of mitosis, thus causing their degra-1982 Cell Reports 18, 1982–1995, February 21, 2017 ª 2017 The Aut
This is an open access article under the CC BY-NC-ND license (http://dation and allowing mitosis to proceed (Pines, 2011). Premature
activation of the APC/C can cause mis-segregation of chromo-
somes and thus lead to aneuploidy and cancer. Critical sub-
strates of the APC/C include the mitotic cyclins and Securin.
The APC/C has two protein co-activators, Cdc20 and Cdh1,
which control the initiation of anaphase and exit of mitosis,
respectively. Many proteins have been discovered that regulate
APC/C activity including Emi1, RASSF1A, TIF1g, andMDC1 (Re-
imann et al., 2001; Sedgwick et al., 2013; Song et al., 2004;
Townsend et al., 2009). Additionally, the APC/C has an inhibitory
complex known as the spindle assembly checkpoint (SAC) that
restrains the APC/C until the chromosomes have been properly
aligned at metaphase. Although there are many anti-mitotic
drugs that ultimately act on the APC/C by activating the SAC
(Smolders and Teodoro, 2011), it has been recently demon-
strated that directly inhibiting the APC/C might be an effective
mechanism for killing cancer cells (Sackton et al., 2014).
Several studies have suggested that there is considerable
crosstalk between DNA damage response (DDR) signaling and
the APC/C. The Cdh1 inhibitor Mad2L2 was recently shown to
participate in DNA repair (Boersma et al., 2015; Xu et al.,
2015). A large-scale proteomic study also found that the
APC/C associated with three members of the tandem BRCA1
repeat BRCT1 C-terminal (tBRCT) family including MDC1,
PAXIP1, and 53BP1 (Woods et al., 2012). Although these studies
suggest a close relationship between the APC/C and DDR, the
mechanism and biological significance are poorly understood.
53BP1 is a well-characterized member of the tBRCT family. It
contains several functional domains including an oligomerization
domain, a tandem tudor domain, and a tBRCT domain, all con-
tained in the C-terminal third of the protein (FitzGerald et al.,
2009). In contrast, little is known about the N-terminal region of
53BP1 other than it is rich in ATMconsensus sites and it is impor-
tant for DNA repair functions (Di Virgilio et al., 2013; Zimmermann
et al., 2013). 53BP1 has been extensively studied in its role in the
DDR, which is to promote non-homologous end joining DNA
repair (Panier and Boulton, 2014).
Mice lacking either one or both 53BP1 alleles were shown to
be cancer-prone, suggesting that the protein is a bona fide tumorhor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
suppressor. However, in addition to structural chromosomal ab-
errations, there was a notable increase in aneuploidy both in tu-
mors and in primary splenocytes, showing that 53BP1 knockout
results in CIN, which is inconsistent with the known functions of
53BP1; for this reason it has been proposed that 53BP1 has
additional functions in suppressing CIN (Morales et al., 2006;
Ward et al., 2005). Recently, three studies have suggested that
53BP1 has a role in the response to mitotic stress induced
through the centrosome; however, the mechanistic details are
still lacking (Fong et al., 2016; Lambrus et al., 2016; Meitinger
et al., 2016).
In the current study we demonstrate that 53BP1 is degraded
early in mitosis through an APC/C-dependent mechanism
requiring evolutionarily conserved KEN boxes on 53BP1. We
observed that 53BP1 interacts with the APC/C using the KEN
boxes and the tBRCT domain. Cells expressing a stable mutant
of 53BP1 took longer to progress through mitosis. Conversely,
cells lacking 53BP1 took shorter times to progress through
mitosis and were extremely sensitive to spindle poisons. Addi-
tionally, 53BP1 inhibited the APC/C both in vivo and in vitro.
Taken together, our results suggest the tumor-suppressor prop-
erties of 53BP1 are due in part to its ability to inhibit the APC/C,
thus ensuring the proper progression of mitosis.
RESULTS
53BP1 Levels Are Decreased during Mitosis in an
APC/C- and Proteasome-Dependent Manner
Inspection of the amino acid sequence of human 53BP1 shows
that the protein contains three KEN boxes, at positions 54, 85,
and 1136. Interestingly, comparison of amino acid sequences
of 53BP1 across species shows that the presence of at least
one KEN box is conserved from yeast to humans. Importantly,
all three KEN boxes are present in disordered regions of
53BP1. Therefore, it is likely that 53BP1 is an APC/C substrate.
To test this hypothesis, we synchronized HeLa cells in late G2
with the cyclin-dependent kinase-1 (CDK1) inhibitor RO3306,
released them intomitosis, andmonitored 53BP1 levels by west-
ern blot. Following release into mitosis, 53BP1 levels decreased
significantly in a comparable manner with that of cyclin B1 and
other known APC/C substrates (Figure 1A). We observed the
same effect by fluorescence microscopy (Figure 1B).
To verify that 53BP1 levels decrease via the proteasome, HeLa
cells were released into mitosis in the presence of the protea-
some inhibitor MG132. 53BP1 levels were reduced in control
cells but were rescued in cells treated with MG132 (Figure 1C).
Cyclin B1 levels were similarly elevated following treatment
with MG132. To further show that the APC/C targets 53BP1 for
degradation during mitosis, we utilized an inhibitor of the
APC/C, proTAME (tosyl arginine methyl ester) (Zeng and King,
2012). HeLa cells were synchronized using RO3306 and then
released into media containing proTAME. Figure 1D shows
that 53BP1 protein levels remain elevated in proTAME-treated
cells, as does cyclin B1.
To determine which APC/C co-activator recognizes 53BP1
during mitosis, we knocked down Cdc20, Cdh1, or a core
APC/C subunit, APC3, using small interfering RNAs (siRNAs).
HeLa cells were synchronized in G2 with RO3306, releasedinto mitosis, and harvested. Surprisingly, knockdown of both
co-activators resulted in the partial rescue of 53BP1 protein
levels, compared with the complete loss of 53BP1 protein levels
in non-silencing controls (NSCs), and the full rescue of 53BP1
in APC3 knockdown cells (Figure 1E). Taken together, these
data show that 53BP1 is a substrate of both APC/CCdc20 and
APC/CCdh1.
53BP1 Is Degraded during Mitosis Independently of
the SAC
In order to examine the relationship between the SAC and 53BP1
degradation, we synchronized HeLa cells via thymidine-nocoda-
zole. Mitotic cells were collected by shake-off and released into
either fresh media or media containing Taxol. 53BP1 protein
levels remained extremely low in Taxol-treated cells and did
not increase until the cells had begun to exit mitosis via slippage
(Figure 2A). In contrast, cyclin B1 and Securin levels were stabi-
lized in Taxol-treated cells, as is expected when the SAC is
engaged. The APC/C substrates cyclin A2 and Nek2A are insen-
sitive to SAC inhibition because they bind to the APC/C indepen-
dently of Cdc20 (Di Fiore and Pines, 2010; Hayes et al., 2006).
We similarly observed that cyclin A2 and 53BP1 were low in
the presence of Taxol, indicating that 53BP1 can also be
degraded while the SAC is engaged (Figure 2A). We also tested
cells released from thymidine arrest to see whether 53BP1 levels
decrease upon mitotic entry. We observed that 53BP1 levels
increased in G2 and then declined as the cells entered mitosis.
In cells released from thymidine to RO3306, the levels of
53BP1 did not decrease because the cells did not enter mitosis
(Figure 2B).
Because both 53BP1 and cyclin A2 are targeted for APC/C-
Cdc20-mediated degradation early in mitosis, we askedwhether
53BP1 binds to Cdc20 and whether this interaction occurs prior
to the onset of mitosis. HeLa cells were synchronized in G2 with
RO3306 or inmitosis with nocodazole. Cdc20was then immuno-
precipitated, separated on SDS-PAGE, and immunoblotted for
53BP1 and cyclin A2. As expected, binding of cyclin A2 to
Cdc20 was detected only in G2 cells (Figure 2C) (Wolthuis
et al., 2008). Interestingly, we also detected binding of 53BP1
to Cdc20 in cells under similar conditions. In slight contrast
with cyclin A2, we also detected binding of 53BP1 by Cdc20 in
asynchronous cells. These data suggest that 53BP1 is pre-
bound to the APC/C in a similar manner as cyclin A2.
If 53BP1 is indeed a mitotic APC/C substrate that is ubiquiti-
nated independently of SAC activity, then it should be ubiquiti-
nated by the APC/C in the presence of nocodazole. To verify
that this is the case, we performed an in vivo ubiquitination assay
according to established protocols (Bloom and Pagano, 2005).
We treated the cells with nocodazole andMG132, and examined
the levels of ubiquitination on 53BP1. Levels of 53BP1 were
normalized between the asynchronous and nocodazole-treated
samples. We observed that the 53BP1 frommitotic cells is mark-
edly more ubiquitinated compared with 53BP1 from asynchro-
nous cells (Figure 2D). It has been demonstrated that the
APC/C forms both K11- and K48-linked ubiquitin chains (Matsu-
moto et al., 2010; Wickliffe et al., 2011). To provide additional
evidence that 53BP1 is an APC/C substrate, we blotted the
same samples with an anti-K11 chain antibody. Western blotCell Reports 18, 1982–1995, February 21, 2017 1983
Figure 1. 53BP1 Levels Are Decreased during Mitosis in an APC/C- and Proteasome-Dependent Manner
(A) HeLa cells were synchronized with RO3306 over 20 hr, released into fresh media, and harvested at the indicated times. Equal quantities of total cell extract
were loaded in each lane and separated by SDS-PAGE, and the levels of proteins were monitored by immunoblot. Asterisk (*) indicates the true Cdc20 band.
(B) HeLa cells were plated and allowed to grow for 36 hr before fixation. 53BP1was then stained together with DAPI. TheDAPI imagewas enhanced for brightness
and contrast for presentation. Fluorescence levels of 53BP1 for at least 25 cells per condition were quantified with ImageJ and plotted. Error bars indicatemean ±
SEM. Statistical significance was calculated using Student’s two-tailed t test. ****p < 0.0001.
(C) HeLa cells were synchronized as in (A) but released into control medium or medium containing MG132. The cells were harvested 2 hr post release and
analyzed as in (A).
(D) Cells were synchronized as above but either released into control medium or medium containing proTAME. The cells were then harvested and analyzed as
above.
(E) HeLa cells were transfected with the indicated siRNAs, synchronized with RO3306 over 20 hr, released, and harvested. The cells were then analyzed as in
(A)–(C). Asterisk (*) indicates the true Cdc20 band.analysis revealed that in the presence of nocodazole, 53BP1was
ubiquitinated with K11-linked chains, which was enhancedwhen
cells were treated with MG132 (Figure 2D).
To confirm that 53BP1 ubiquitinated species are K11 linked,
we utilized a ubiquitin mutant lacking all available lysines except
for K11. If 53BP1 is ubiquitinated by the APC/C, then this ubiqui-
tin mutant should be incorporated into ubiquitin chains. There-
fore, we compared the incorporation of wild-type (WT) ubiquitin
with K11-only ubiquitin. Levels of 53BP1 expression were
normalized across the samples. We found that the K11 mutant
ubiquitin is efficiently ligated to 53BP1 (Figure S1A). This effect1984 Cell Reports 18, 1982–1995, February 21, 2017was not observed using a control substrate, caspase 1 (Fig-
ure S1B), which is regulated by K63-linked ubiquitin chains
(Labbe´ et al., 2011). Taken together, these results establish
that 53BP1 interacts with Cdc20 and is ubiquitinated by the
APC/C during mitosis even in the presence of an active SAC.
53BP1 Requires KEN Boxes for Cdc20 Interaction and
Degradation during Mitosis
To determine whether the KEN boxes present in 53BP1 are
required for degradation during mitosis, we derived FLAG-
tagged mutants in which all the KEN boxes of 53BP1 were
Figure 2. 53BP1 Is Degraded during Mitosis Independently of the SAC
(A) HeLa cells were synchronized by thymidine-nocodazole. Mitotic shake-off cells were collected, washed twice with PBS, and then released into fresh medium
or medium containing Taxol. Cells were then harvested at various time points as shown. The cells were then processed and protein levels monitored by
immunoblot.
(B) HeLa cells were synchronized by double-thymidine block and then released into fresh media. Five hours post release, nocodazole or RO3306 was added. The
cells were harvested at time points as indicated. The cells were then processed as in (A).
(C) HeLa cells were plated and synchronized as indicated. Cdc20 was then immunoprecipitated and then analyzed together with interacting proteins by
immunoblot. Asterisk (*) indicates the true band.
(D) 293T cells were co-transfected with 3XFLAG-53BP1 and HA-ubiquitin. They were then treated with nocodazole for 20 hr, then MG132 for 4 hr. The cells were
then harvested and 3XFLAG-53BP1 was immunoprecipitated in RIPA buffer. The proteins were then eluted, separated by SDS-PAGE, and analyzed for ubiq-
uitination by immunoblot. 53BP1 levels were normalized prior to gel loading.
See also Figure S1.mutated to alanine residues (KEN-AAA). HeLa cells were trans-
fected with the WT and mutant 53BP1 constructs, synchronized
in mitosis, and then harvested. Western blot showed that
whereas levels of WT 53BP1 protein were reduced in mitotic
cells, the protein levels of the 53BP1 KEN box mutant remained
constant (Figure 3A).
Because the KEN box mutant is more stable compared with
WT 53BP1, it follows that it should also have lower affinity for
Cdc20. To test this, we immunoprecipitated Cdc20 from 293T
cells transfected with WT 53BP1 or KEN-AAA 53BP1. Levels of
53BP1 expression were normalized between samples. Figure 3B
shows that WT 53BP1 co-immunoprecipitated with Cdc20 inboth asynchronous and mitotic cells. In contrast, the KEN box
mutant associated with Cdc20 in asynchronous cells, but not
in mitotic cells. These data suggest that 53BP1 binds Cdc20
via its KEN boxes inmitotic cells, but through a separate site dur-
ing interphase.
Because the 53BP1 KEN box mutant is defective for binding
to Cdc20, it should be ubiquitinated less efficiently than WT
53BP1. To test this hypothesis, we utilized an in vivo ubiquitina-
tion assay and compared the ubiquitination of WT 53BP1 and
the KEN-AAA mutant. Figure 3C shows that whereas WT
53BP1 was robustly ubiquitinated, the KEN box mutant was
not. Therefore, we conclude that the KEN boxes of 53BP1Cell Reports 18, 1982–1995, February 21, 2017 1985
Figure 3. 53BP1 Requires KEN Boxes for Cdc20 Interaction and Degradation during Mitosis
(A) HeLa cells were transfected with 3XFLAG-53BP1 WT or KEN-AAA mutant. The cells were then synchronized by thymidine-nocodazole and harvested. Equal
quantities of total cell extract were separated by SDS-PAGE, and expression of 3XFLAG-53BP1 was analyzed by immunoblot.
(B) 293T cells were co-transfected with 3XFLAG-53BP1 WT or KEN-AAA mutant. The cells were then synchronized by thymidine-nocodazole. Cdc20 was then
immunoprecipitated and interacting proteins analyzed by western blot. Asterisk (*) indicates the true Cdc20 band.
(C) 3XFLAG-53BP1 WT or KEN-AAA were co-transfected together with HA-tagged ubiquitin. 53BP1 was then purified by FLAG-IP, and ubiquitin content was
analyzed by western blot. 53BP1 levels were normalized prior to gel loading.
(D) 53BP1/ cells were transfected with 3XFLAG WT or KEN-AAA constructs. The cells were then synchronized by thymidine block and released into fresh
media. The time spent by 100 cells in mitosis under each condition is shown.
(E) Average time spent in mitosis by the cells shown in (D). Error bars indicate mean ± SEM. Statistical significance was calculated using Student’s two-tailed
t test. ***p = 0.0006.
See also Figure S2.are required for binding to Cdc20 and 53BP1 degradation dur-
ing mitosis.
We next tested whether mutation of the 53BP1 KEN boxes
results in altered protein function. We first tested the ability of
KEN-AAA to form foci at sites of DNA damage in response to
ionizing radiation. Wild-type or mutant 53BP1 were expressed
in 53BP1/ HeLa cells generated by CRISPR (Feng et al.,
2015) and displayed no apparent differences in either the ability
to form foci or their persistence following 5 Gy of radiation (Fig-
ure S2B). We then tested the effect of expressing the KEN box
mutant on mitotic progression. Compared with WT 53BP1,
expression of the KEN-AAA resulted in mitosis 30% longer on1986 Cell Reports 18, 1982–1995, February 21, 2017average (Figures 3D and 3E). We also monitored the expression
of various APC/C targets during mitosis. Consistent with the
time-lapse experiments, we found a delay in the degradation
of APC/C substrates, suggesting delayed mitotic exit in cells ex-
pressing the KEN box mutant (Figure S2A).
Cdc20 Binds to the N Terminus and tBRCT Domains of
53BP1, Whereas Cdh1 Binds Exclusively to 53BP1
tBRCT Domains
In order to better understand the mechanism of 53BP1 associa-
tion with the APC/C, we performed a structure-function analysis.
A series of deletion mutants of 53BP1 were derived, which are
Figure 4. Cdc20 Binds to the N Terminus and tBRCT Domains of 53BP1, Whereas Cdh1 Is Bound Exclusively through the tBRCT Domains
(A) 293T cells were co-transfected with 3XFLAG-53BP1 constructs and HA-Cdc20. At 48 hr following transfection the cells were harvested, and 3XFLAG-53BP1
was immunoprecipitated and tested for the presence of HA-Cdc20 by immunoblot.
(B) 293T cells were co-transfected with 3XFLAG-53BP1 WT and HA-Cdc20 constructs and analyzed as in (A).
(C) 293T cells were co-transfected with 3XFLAG-53BP1 constructs and HA-Cdh1 constructs and analyzed as in (A).
(D) 293T cells were co-transfected with 3XFLAG-53BP1 WT and HA-Cdh1 constructs and analyzed as in (A).
(E) Schematic of 3XFLAG-53BP1 constructs.
(F) Schematic of Cdc20 and Cdh1 constructs.
See also Figure S3.depicted in Figure 4E. 293T cells were co-transfected with Flag-
tagged WT or deletion mutants of 53BP1 and hemagglutinin
(HA)-tagged Cdc20. 53BP1 complexes were immunoprecipi-
tated and tested for the presence of HA-Cdc20. As expected,
Figure 4A shows that the 53BP1 fragments containing KEN
boxes efficiently immunoprecipitated Cdc20. Surprisingly, the
tBRCT domains also associated with Cdc20. Because 53BP1
appears to interact with Cdc20 through two separate domains,
we asked whether the binding between 53BP1 and Cdc20 is
cell cycle dependent. Interestingly, whereas the 1–609 KEN-
box-containing fragment of 53BP1 bound to Cdc20 in both
interphase and mitotic cells, the 1220–1972 tBRCT-domain-
containing fragment bound to Cdc20 only in interphase cells
(Figure S3A). Thus, the binding mode of 53BP1 to Cdc20
appears to depend upon cell cycle state.
To determine the regions of Cdc20 required for association
with 53BP1, we derived a series of Cdc20 deletion mutants (Fig-ure 4F). Analysis of these mutants showed that 53BP1 associ-
ates with the disordered N terminus of Cdc20 and to a lesser
extent with the WD40 domain (Figure 4B).
Knockdown of Cdh1 also resulted in stabilization of 53BP1
(Figure 1E), suggesting both the Cdc20 and Cdh1 APC/C co-ac-
tivators may bind 53BP1. In Figure 4C we show that exogenous
Cdh1 does co-immunoprecipitation (IP) with 53BP1. In contrast
with Cdc20, however, Cdh1 exclusively associated with the
tBRCT domain of 53BP1. We similarly mapped the region on
Cdh1 required for binding to 53BP1 and found that the C-termi-
nal WD40 domain was essential (Figure 4D). To test whether the
tBRCT domain of 53BP1 binds to a phosphorylated site onCdh1,
we generated a point mutant of 53BP1 (K1814M) that cannot
bind to phosphorylated proteins (Kleiner et al., 2015). Compared
with wild-type 53BP1, thismutant is defective in binding toCdh1,
suggesting that the interaction between the 53BP1 tBRCT
domain and Cdh1 is regulated by phosphorylation (Figure S3D).Cell Reports 18, 1982–1995, February 21, 2017 1987
(legend on next page)
1988 Cell Reports 18, 1982–1995, February 21, 2017
Because the interaction between 53BP1 and both APC/C co-
activators required the tBRCT domain of 53BP1, it is possible
that this interaction is also required for the degradation and ubiq-
uitination of 53BP1. We tested the ability of the 53BP1 fragments
to be degraded in mitosis. We found that in small fragments of
53BP1, the presence of a KEN box is sufficient to mediate the
degradation of the protein. However, in a large fragment of
53BP1, the tBRCT domain is also required (Figure S3B). We
then performed an in vivo ubiquitination experiment using the
panel of 53BP1 fragments (Figure S3C). Consistent with the
degradation experiment, a 53BP1 mutant lacking the tBRCT
domain was poorly poly-ubiquitinated, whereas a 53BP1 dele-
tion mutant comprised of only the 53BP1 C-terminal region
was extensively ubiquitinated, indicating that the tBRCT domain
is required for 53BP1 to be efficiently ubiquitinated in vivo.
53BP1 Is Required for Normal Cell Cycle Progression,
and Reduced Expression Sensitizes Cells to Mitotic
Poisons
Because we observed that expressing the 53BP1 KEN box
mutant resulted in slow mitotic progression, we asked whether
reducing 53BP1 levels might also have an effect. 53BP1 was
knocked down in HeLa cells using siRNAs, which were then syn-
chronized with thymidine-nocodazole, and cell cycle analysis
was performed. Figure 5A shows that when 53BP1 was knocked
down in asynchronous cells there was a 50% reduction in the
percentage of cells in mitosis as determined by measuring
pSer28 histone H3-positive cells. The phenotype of 53BP1
knockdown was far more apparent in synchronized cells. Fig-
ure 5A shows that whereas cells transfected with NSC siRNAs
contained mostly cells arrested in G2/M (71.3%), 53BP1 knock-
down populations had approximately half the number of G2/M
cells (30.7% and 38.5%). Interestingly, many 53BP1 knockdown
cells displayed sub-2N DNA content (7.1% of NSCs compared
with 24.5% and 23.4% in 53BP1-knockdown cells), indicating
that the combination of 53BP1 knockdown and nocodazole
was inducing cell death. Similar effects were observed using
Taxol.
We then asked whether the defects in cell cycle progression
that we observed were at the point of thymidine arrest or noco-
dazole arrest. Therefore, we repeated the siRNA transfection
and treated the cells with thymidine only. The cells were then har-
vested and analyzed by flow cytometry. Interestingly, we
observed a profound defect in the ability of the si53BP1-trans-
fected cells to advance fromG1 to S phase (Figure 5C), suggest-
ing that the inability of the cells to synchronize in mitosis is in fact
due to an inability of cells to advance into S phase.Figure 5. 53BP1 Is Critical for Normal Cell Cycle Progression
(A) HeLa cells were transfected with siRNAs as indicated. Twenty-four hours follow
for 4 hr, and treated with nocodazole for 16 hr. Following treatment the cells w
histone H3.
(B) HeLa cells were transfected as in (A), but processed for SDS-PAGE. Equal quan
by immunoblot.
(C) HeLa cells were transfected with siRNA as indicated. They were then treated
content.
(D) HeLa cells were transfected with siRNA and DNA as indicated. They were th
(E) HeLa cells were treated as in (C), but processed for SDS-PAGE as in (B).Finally, we asked whether an RNAi-resistant 53BP1 cDNA
could rescue the effects of 53BP1 knockdown. Indeed, transfec-
tion of the 53BP1-expressing cDNA reduced the number of cells
with sub-2N DNA content as well as increasing numbers of cells
in G2/M (Figures 5D and 5E), confirming that our observations
were due to 53BP1 knockdown.
To further investigate the phenotypes of 53BP1 knockdown,
we utilized time-lapse microscopy and single-cell analysis.
HeLa cells were transfected with siRNAs to knock down
53BP1, synchronized with thymidine, and released. Figure 6A
shows that in contrast with cells expressing the stable 53BP1
KEN box mutant, knockdown cells spent less time in mitosis.
On average, NSC cells spent 124.4 min in mitosis compared
with 69.2 min (si53BP1-1) and 45.2 min (si53BP1-2). Despite
transiting through mitosis more rapidly, 53BP1 knockdown cells
were often delayed in mitotic entry and in many cases did not
enter mitosis (Figure 6B; Movies S1 and S2).
Release of thymidine synchronized 53BP1 knockdown cells
into nocodazole resulted in a more dramatic effect. The combi-
nation of 53BP1 knockdown and nocodazole treatment was
highly toxic; only 8% (si53BP1-1) and 35% (si53BP1-2) of cells
underwent mitotic slippage and entered into G1 compared
with 73% of NSC cells (Figure 6C; Movies S3 and S4). Examples
are provided in Figure S4A. Interestingly, we observed a long
delay in the ability of 53BP1 knockdown cells, relative to
NSCs, to commit tomitotic entry, consistent with the flow cytom-
etry analysis. A similar pattern was observed in cells treated with
Taxol (Figure 6D; Movies S5 and S6). These effects were not
limited to HeLa cells and were also observed in other cell lines
including H1299, 293T, and PC3. These effects were not
restricted to cancer cells because similar results were obtained
using BJ fibroblasts, suggesting that the replication stress com-
mon in cancer cells is not required for these phenotypes (Fig-
ure S4B). Additionally, similar results were obtained without
using thymidine to pre-synchronize the cells, ruling out possible
DNA damage effects (Figure S4C). Moreover, 53BP1/ HeLa
cells displayed a similar phenotype as cells transfected with
siRNA (Figure S5C and data not shown).
Because cells lacking 53BP1expression take less time to com-
pletemitosis comparedwith theNSCcells, we askedwhether the
53BP1 knockdown cells would also have a higher incidence of
anaphase defects. To address this question, we used the cell
line HCT116 because of its stable, near-diploid karyotype. We
therefore knocked down 53BP1 in this cell line and 48 hr later
fixed the cells and stained them with DAPI. We then examined
the cells in anaphase for the presence of lagging chromosomes,
anaphase bridges, and multi-polar spindles. Examples areing transfection, the cells were synchronized by thymidine over 20 hr, released
ere harvested and analyzed by flow cytometry for DNA content and pSer28
tities of total cell extract were separated, and the protein levels weremonitored
with thymidine for 20 hr, harvested, and analyzed by flow cytometry for DNA
en treated and processed as in (A).
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shown in Figure S4D. We found that the 53BP1 knockdown cells
had 1.9-fold (si53BP1-1) and 2.1-fold (si53BP1-2) more defects
overall compared with the NSC cells (Figure S4B). Taken
together, the results demonstrate that cells lacking 53BP1 have
a number of cell cycle defects: they struggle to enter mitosis
and transit through mitosis faster, resulting in anaphase defects.
53BP1 Regulates APC/C Activity
Because we observed that 53BP1 interacts with APC/C co-acti-
vators and modulation of 53BP1 affected mitotic progression,
we therefore asked whether these effects were due to changes
in APC/C activity. We first determined the effect of 53BP1
knockdown on the levels of known APC/C substrates. 53BP1
expression was silenced and levels of APC/C substrates were
determined by immunoblot. Figure 7A shows that the APC/C
substrates BubR1, Cdc20, cyclin B1, cyclin A2, Securin, PLK1,
and Cdc6 were all reduced in 53BP1 knockdown cells relative
to NSCs. This phenotype was also present in 53BP1/ HeLa
cells (Figure S5A). Consistent with a role for 53BP1 in specifically
regulating APC/C activity, the levels of cyclin E, which is not an
APC/C substrate, were unaffected by the depletion of 53BP1
in asynchronous cells (Figure 7A). Differences in the levels of
APC/C substrates between NSC and si53BP1 knockdown in
asynchronous cells cannot be attributed to differences in cell
cycle state because the cell cycle profiles are very similar in
the two populations (Figure 5A). To confirm that reduction of
APC/C substrates was due to 53BP1 knockdown, we tested
whether siRNA-resistant cDNA could rescue APC/C substrate
levels. The levels of cyclin B1, Cdc20, and BubR1 were all
restored to normal following the exogenous expression of
53BP1 (Figure 7B). Because the levels of the APC/C substrates
are low after depletion of 53BP1, these data suggest that
53BP1 may function as an APC/C inhibitor.
If the reduced levels of APC/C substrates in 53BP1 knock-
down cells were due to high APC/C activity, then substrates
would be predicted to be less stable. To test this idea, we per-
formed a cycloheximide chase experiment. Figure S6A shows
that the APC/C substrates had a decreased half-life in 53BP1
knockdown cells compared with NSCs. Consistent with a role
for proteasome-mediated degradation in the reduction in the
levels of APC/C substrates, the levels of these proteins were
restored in the presence of MG132 (Figure S6B). To further
demonstrate that 53BP1 negatively regulates APC/C activity,
we tested the ability of cell extracts prepared from cells treated
with either NSCs or si53BP1 to ubiquitinate cyclin B1. Consistent
with a model where 53BP1 is a repressor of APC/C function,Figure 6. 53BP1 Knockdown Promotes Cell Death in Mitosis in the Pre
(A) HeLa cells were transfected overnight with siRNAs as indicated. Twenty-four h
were washed twice with PBS and released into fresh media, and time-lapse imag
mitosis was plotted. Cells that died or did not enter mitosis were excluded from t
presented as the mean ± SEM of a single representative experiment. Statistical
(B) The time spent in interphase and mitosis, as well as the fate of 100 cells from
enter mitosis were included in the analysis.
(C) HeLa cells were transfected overnight with siRNAs as indicated. Twenty-fo
Following 4 hr release from thymidine, nocodazole was added and time-lapse ima
cells, was plotted.
(D) Cells were treated as in (C) except that the cells were released into 100 nM T
For all panels the median time for the NSC cells is indicated. See also Figures Scyclin B1 was more efficiently ubiquitinated by the extracts of
53BP1 knockdown cells (Figure 7C).
During mitosis the SAC acts as an essential APC/C inhibitor.
To rule out the possibility that 53BP1 may be inhibiting APC/C
through the SAC, we determined whether 53BP1 associates
with the SAC. 293T cells were transfected with FLAG-tagged
53BP1 or Cdc20. Immunoprecipitation of the FLAG-tagged pro-
teins was performed and tested for the presence of the SAC
components Bub1, BubR1, and Mad2. Although Cdc20 inter-
acted robustly with these proteins, no interaction was observed
between 53BP1 and the SAC (Figure S6C). Therefore, 53BP1
appears to inhibit the APC/C independently of the SAC.
As a final demonstration that 53BP1 can function as a direct
APC/C inhibitor, we produced recombinant 53BP1 (r53BP1) in
E. coli (Figure S6D) and tested its ability to inhibit the APC/C
in vitro. Figure 7D shows that r53BP1 inhibited theAPC/C-depen-
dent ubiquitination of cyclin B1 with comparable efficiency as
Emi1 at concentrations shown previously to inhibit the APC/C
(Wang and Kirschner, 2013). The ability of 53BP1 truncation mu-
tants to inhibit APC/C-directed ubiquitination of cyclin B1 was
also assessed. Figure 7E shows that when used individually,
53BP1 fragments failed to block cyclin B1 ubiquitination.
Because we found that both the N and C termini of 53BP1 can
independently bind to the APC/C, we reasoned that both of these
regions might be required to block APC/C activity. Therefore, we
tested the ability of the 1–609 and 1220–1972 fragments to block
the ubiquitination reaction in trans. Indeed, the combination
caused a modest decrease in ubiquitination of cyclin B1. We
next tested whether the 53BP1 KEN boxes are required for the
effective inhibition of the APC/C.We found no difference in inhibi-
tion of the APC/C between WT and KEN box mutant 53BP1
(Figure S6E), indicating that the KEN boxes on 53BP1 are
dispensable for APC/C inhibition. Importantly, this result indi-
cates that 53BP1 is not acting as a pseudosubstrate inhibitor by
saturating the KEN box binding sites of the APC/C co-activators.
Given that 53BP1 functions as an APC/C inhibitor, we asked
whether chemical inhibition of the APC/C using proTAME could
rescue the deleterious effects of 53BP1 knockdown. Figure 7F
shows that whereas proTAME had no effect on the ability of cells
transfected with the NSC siRNA to enter mitosis, it largely
rescued the phenotypes of 53BP1 knockdown both with respect
to the lag in mitotic entry and the lethality of nocodazole (Fig-
ure 7F; Movies S7 and S8). The rescue of the 53BP1 silencing
phenotypes by addition of proTAME indicates that the source
of the cell cycle defects was due to excess APC/C activity. Taken
together, our data suggest that 53BP1-mediated inhibition of thesence of Spindle Poisons
ours following transfection, the cells were synchronized by thymidine. The cells
ing was started. The average time spent in mitosis by 100 cells that completed
he analysis. The average time spent in mitosis is indicated (right). The data are
significance was tested for Si53BP1-1 and si53BP1-2 against the NSC cells.
the same experiment as (A), was plotted, except that cells that died or did not
ur hours following transfection, the cells were synchronized using thymidine.
ging started. The time spent in interphase andmitosis, as well as the fate of 100
axol.
4 and S5.
Cell Reports 18, 1982–1995, February 21, 2017 1991
Figure 7. 53BP1 Regulates APC/C Activity
(A) HeLa cells were transfected with siRNAs as indicated. Twenty-four hours following transfection, cells were either left asynchronous or synchronized by
thymidine-nocodazole. The cells were then harvested, equal quantities of total cell extract were separated by SDS-PAGE, and the levels of proteins were
monitored by immunoblot. Asterisk (*) indicates the true Cdc20 band.
(B) HeLa cells were transfected with siRNA and DNA as indicated. At 48 hr following transfection, the cells were harvested, equal quantities of total cell extract
were separated by SDS-PAGE, and the levels of proteins were monitored by immunoblot. Asterisk (*) indicates the true Cdc20 band.
(C) HeLa cells were transfected overnight with siRNAs as indicated. At 48 hr following transfection, cells were harvested and lysed. Equal quantities of cell extract
were incubated together with 35S-labeled cyclin B1, ubiquitin, and an ATP regenerating system. Following 60min incubation the reaction was stopped by addition
of 43 sample buffer and separated on SDS-PAGE. The gel was then dried and exposed.
(D) Exponentially growing HeLa cells were harvested and lysed. APC3 was then immunoprecipitated and mixed with recombinant E1 and E2 enzymes, ubiquitin,
35S-labeled cyclin B1, and an ATP-regenerating system together with recombinant proteins as indicated. The reaction was then incubated at 37C and stopped
after 10 min by addition of 43 sample buffer. The reactions were then resolved on SDS-PAGE and the gels treated for fluorography and finally exposed to film.
Emi1 300-447 is a positive control for APC/C inhibition.
(E) A reconstituted ubiquitination assay was prepared as in (D), but with various 53BP1 constructs as indicated.
(F) HeLa cells were transfected overnight with siRNAs as indicated. Twenty-four hours following transfection, the cells were synchronized with thymidine or
thymidine and 20 mM proTAME. Following 3 hr release from thymidine, nocodazole was added and time-lapse imaging started. The time spent in interphase and
mitosis, as well as the fate of 100 cells, was plotted.
See also Figure S6.APC/C is required for cell cycle progression and the cellular re-
sponses to mitotic stress.
DISCUSSION
In this study we describe a mechanism by which the 53BP1 pro-
tein negatively regulates APC/C activity by binding through its1992 Cell Reports 18, 1982–1995, February 21, 2017tBRCT domains to the APC/C co-activators Cdc20 and CDH1.
Early in mitosis the APC/C ubiquitinates 53BP1 in a KEN-box-
dependent manner and thereby relieves the 53BP1-dependent
inhibition of the APC/C. We found that 53BP1 also binds to
Cdc20 through its tBRCT domain in interphase cells, but via
the KEN boxes only during mitosis. Mutation of the 53BP1
KEN boxes resulted in cells with a slow transit through mitosis,
and conversely, knockdown of 53BP1 accelerated mitotic
transit. Our findings suggest a reciprocal regulation of APC/C
and 53BP1 that is important for cell cycle progression.
APC/CCdh1 maintains the G1 state. Therefore, we propose
53BP1 helps allow the transition to S phase and G2 by inhibiting
the APC/C. Once the cell reachesmitosis, 53BP1 is ubiquitinated
and degraded to allow mitotic progression.
Interestingly, the tBRCT domains of 53BP1, MDC1, MCPH1,
and PAXIP1 (Coster et al., 2007; Singh et al., 2012; Townsend
et al., 2009; Woods et al., 2012) have all been shown to interact
with the APC/C, consistent with our observations. Interestingly,
MDC1 appears to have the opposite effect of 53BP1 in regulating
the activity of the APC/C, because knockdown of MDC1 causes
mitotic arrest because of a lack of APC/C activity (Townsend
et al., 2009). Therefore, a balance between several BRCT-con-
taining proteins may act to properly regulate APC/C activity.
The DDR is largely inactivated during mitosis, leaving only api-
cal DDR signaling by ATM and gH2AX to label DNA breaks for
repair in G1 (Giunta et al., 2010; Nelson et al., 2009; Orthwein
et al., 2014; van Vugt et al., 2010). Relevant to our study, DNA
damage foci during mitosis have been shown to completely
lack 53BP1, suggesting a strong negative regulation (Nelson
et al., 2009). It is now clear that active DNA repair during mitosis
is deleterious, because 53BP1 activity during mitosis increases
genomic instability (Lee et al., 2014; Orthwein et al., 2014). There-
fore, APC/C-dependent degradation of 53BP1might be an addi-
tional mechanism by which the DDR is switched off in mitosis.
We found that the interaction between 53BP1 and the APC/C
co-activators occurs through both the KEN boxes and tBRCT
domain of 53BP1. This dual mode of binding creates a constitu-
tive interaction between 53BP1 and the Cdc20, allowing 53BP1
to be both an APC/C substrate and an inhibitor. It is possible that
the three KEN boxes of 53BP1 create an unusually high affinity
between 53BP1 and the APC/C co-activators, which is consis-
tent with its early degradation in mitosis, akin to cyclin A2 and
Nek2A (Di Fiore and Pines, 2010; Hayes et al., 2006; Wolthuis
et al., 2008). Our observations are in agreement with a recent
study showing that 53BP1 is ubiquitinated in mitotic cells in a
manner that is regulated by the deubiquitinase ubiquitin specific
protease-7 (USP7) (Yim et al., 2016). The ubiquitin ligase was not
identified in this study, but our data suggest that it is the APC/C.
Our data are consistent with several other studies that indicate
a role for 53BP1 in the maintenance of genomic integrity and
proper mitotic progression. Notably, 53BP1 was highlighted in
a screen for proteins that suppress mitotic catastrophe in yeast
(Xia et al., 2001). 53BP1 was also found to repress mitotic catas-
trophe elicited by the HIV Env protein in syncytia (Perfettini et al.,
2010). Furthermore, 53BP1 knockout mice develop highly aneu-
ploid tumors. More recently, it has been shown that 53BP1 is
critical for inducing cell cycle arrest following the induction of
mitotic stress (Fong et al., 2016; Lambrus et al., 2016; Meitinger
et al., 2016). Our data are largely in agreement with their findings
and suggest that the cellular response to mitotic stress might
involve inhibition of the APC/C by 53BP1. Clearly, 53BP1 is not
required for normal mitotic progression because knockout ani-
mals are viable. However, these studies collectively implicate
53BP1 in the response to mitotic stresses, such as that induced
by centrosome depletion or spindle poisons.It has been previously suggested that an efficient way of killing
CIN cells may be to increase the levels of CIN to a catastrophic
threshold where a cell cannot successfully exit mitosis (Janssen
et al., 2009; Silk et al., 2013). In this context, we determined that
knockdown of 53BP1 can be tolerated in unstressed cells, but is
lethal combined with spindle poisons. Given that it has been
shown in principle that chemical inhibition of the APC/C is an
effective way of killing tumor cells (Sackton et al., 2014), it would
also be interesting to determine whether tumors with low 53BP1
expression are hypersensitive to such treatments.
EXPERIMENTAL PROCEDURES
Cell Lines and Treatments
Cells were maintained in DMEM (Wisent) supplemented with 10% fetal bovine
serum (HyClone; Thermo Scientific) and 0.1% gentamicin (Wisent). RO3306
(Sigma-Aldrich) synchronization was performed by treating HeLa cells for
20 hr with 9 mM RO3306. Cells synchronized in mitosis were obtained by
20 hr treatment with 2.5 mM thymidine, 4 hr of release before adding
100 ng/mL nocodazole. proTAME (Boston Biochem) was used at 5–20 mM.
MG132 was purchased from Sigma and used for 4 hr treatments. Cell irradia-
tion was performed with a Radsource RS2000 irradiator at 160 kV and 25 mA.
Plasmids
53BP1 constructs were cloned from N-Myc-53BP1 WT pLPC-Puro Addgene
19836, which was a kind gift of Titia de Lange (Dimitrova et al., 2008), into
p3XFLAG-myc CMV26, pGEX-6P1, or pCDNA3 HA. pCDNA3 HA-CDH1 and
HA-CDC20 were cloned by first producing cDNA from cells by RT-PCR and
then conventional PCR cloning. GST-53BP1 constructs and the Emi1 APC/C
inhibiting domain 300–447 were generated by cloning the sequences into
the pGEX-6P1 vector. PRK5-Ubiquitin WT (17608; Addgene) and K11 only
(22901; Addgene) were kind gifts of Ted Dawson and Sandra Weller (Lim
et al., 2005; Livingston et al., 2009). All constructs were verified by restriction
digestion and sequencing.
Immunoprecipitation and Cell Extracts
293T cells were seeded on 10-cm dishes and transfected overnight using cal-
cium phosphate co-precipitation. Cells were lysed on ice in 1 mL of NP-40,
EDTA, Tris, NaCl (NETN) (Townsend et al., 2009) or radio-immunoprecipitation
assay (RIPA) buffer with protease inhibitor cocktail (Roche). Cell debris was
pelleted by centrifugation at maximum speed for 15 min at 4C. The superna-
tant was then incubated with 10 mL of packed EZview Red anti-FLAG beads
(Sigma-Aldrich) or 10 mL of protein G agarose (EMD Millipore) with the indi-
cated antibody for 2 hr at 4C. The beads were then pelleted, washed five
times with buffer, and then re-suspended in 13 sample buffer. Cell extracts
were prepared by lysing cells as above in NETN buffer, followed by protein
quantification via Bradford assay (Bio-Rad Laboratories).
Ubiquitination Assays
35S-labeled HA-53BP1, HA-cyclinA2, or HA-cyclin B1 were produced by incu-
bating 30 mL of TnT Quick Coupled Transcription/Translation System
(Promega) together with 1 mg of plasmid DNA and 2 mL of [35S]methionine
per reaction (Perkin Elmer). The UBE1, UBCH10, and UBE2S enzymes and
103 Energy Regeneration System (ERS), as well as FLAG-ubiquitin, were
purchased fromBoston Biochem. In vitro ubiquitination was performed essen-
tially as described previously (Kraft et al., 2006). For more details, see the Sup-
plemental Experimental Procedures.
Protein Purification
Expression of the GST-fusion proteins was induced in BL21 E. coli for 4 hr at
37C with 0.2 mM isopropyl b-D-1-thiogalactopyranoside (IPTG). Recombi-
nant proteins were purified on glutathione Sepharose 4B (GE Healthcare)
and eluted with PreScission Protease (GE Healthcare) according to the man-
ufacturer’s instructions. For more details, see the Supplemental Experimental
Procedures.Cell Reports 18, 1982–1995, February 21, 2017 1993
Antibodies and Western Blotting
Western blotting was performed using standard protocols for SDS-PAGE and
wet transfer for at least 24 hr at 30 V onto nitrocellulose membranes (Bio-Rad).
The antibodies are listed in the Supplemental Information. Conditions for west-
ern blots were the use of 5% nonfat dry milk in TBS-T (50 mM Tris [pH 7.5],
150 mM NaCl, 0.5% Tween 20). The bands were visualized by enhanced
chemiluminescence (Western Lightning [PerkinElmer] or SuperSignal West
Femto [Thermo Fisher Scientific]) and exposure on film.
Time-Lapse Microscopy
HeLa cells were seeded on six-well plates and transfected as indicated. Syn-
chronization was performed as described above. Phase-contrast imaging was
performed on a Zeiss Axiovert microscope. Following the addition of nocoda-
zole or Taxol, the cells were placed in an incubation chamber to maintain tem-
perature and CO2 levels during acquisition. For analysis, at least 100 cells were
followed for each condition and the outcome of mitosis recorded. The duration
of mitosis is measured from nuclear envelope breakdown until cytokinesis,
slippage, or death.
siRNA Transfection
HeLa cells were transfected using Lipofectamine 2000 (Invitrogen, Life Tech-
nologies). siRNA sequences and additional details are provided in the Supple-
mental Information.
Flow Cytometry
A Cell Lab Quanta SC flow cytometer (Beckman Coulter) was used to analyze
samples stained either with DAPI to measure DNA content or phospho-Ser28
histone H3 content. The cells were stained and analyzed as previously
described (Darzynkiewicz et al., 2001; Juan and Darzynkiewicz, 2004).
Statistical Methods
Error bars indicate mean ± SEM. Statistical significance was calculated using
Student’s t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2017.01.080.
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